The FDA issued a complete response letter to Mesoblast Limited's (NASDAQ: MESO) resubmission for remestemcel-L for pediatric steroid-refractory acute graft
RBC Capital Markets analyst Drew McReynolds downgraded Thomson Reuters Corp (NYSE: TRI) to Sector Perform from Outperform at an increased price target of $139 from $135,
Exact Sciences Corp (NASDAQ: EXAS) reported Q2 revenue of $622 million, an increase of 19%, and $617 million of core revenue, an increase of 24%, beating the